Arndt Vogel· @ArndtVogel · X·· 2 days agoScore70
Body
FOLFIRI plus ramucirumab vs paclitaxel plus ramucirumab as 2L therapy for taxane-pretreated patients with mGEA–Final results of the phase III IKFs602/AIO RAMIRIS Study
#ESMO26 #ESMOAmbassadors
👉 ORR: 25 vs 23%
👉 mPFS: 5.5 vs 3.7 mo
👉 mOS: 8.7 vs 7.5 mo
🧐neg. study, but FOLFIRI + Ram appears reasonable option
@myESMO @ASCO
425 views · 8 likes · 3 reposts · 0 replies
Conference abstracts
2878ROmatched by Rapid oral 1: Gastrointestinal tumour, upper digestive
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study
https://esmocongress.esmo.orgSource: Arndt Vogel · x.com